Testing a new RET drug for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have documented RET-altered non-small cell lung cancer
- You must be able to sign consent and attend study visits and tests
- Your general health is good (ECOG 0–1) and you’re expected to live more than 3 months
- Your cancer can be measured on scans (measurable disease)
- Your lung cancer is locally advanced or metastatic RET fusion and you could normally receive platinum doublet chemotherapy
- If this is your first cancer treatment for advanced disease, you must not have had a RET-targeted pill or chemotherapy before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a new drug (RC108) combined with furmonertinib, with or without an immune drug (toripalimab), in people with EGFR-mutated lung cancer that has gotten worse after prior EGFR treatment. It aims to see how safe the treatment is and whether it can shrink tumors or help control the disease.
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
This early-phase trial tests lunresertib alone or with other study drugs in people with advanced solid tumors that have certain tumor gene changes. It aims to see whether the treatment is safe and whether it can help shrink or control cancer.
This study tests a targeted pill called pralsetinib given together with a supportive medicine (leucogen) for people whose lung cancer has a specific RET gene change. The goal is to see how well this combination works in everyday hospital care.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.